March 24, 2017
Novartis, PureTech Health team up for the potential treatment of conditions such as immunosenescence
PureTech Health said on Friday that it will advance with Novartis two clinical-stage programmes targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway.